Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + trastuzumab + XELOX
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen consists of fruquintinib, trastuzumab, and the XELOX chemotherapy protocol (oxaliplatin and capecitabine). It is being investigated as a first-line treatment for patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Fruquintinib is a highly selective and potent oral tyrosine kinase inhibitor of VEGFR-1, -2, and -3, which inhibits tumor angiogenesis. Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting tumor cell proliferation. XELOX is a standard chemotherapy regimen where oxaliplatin acts as a DNA alkylating agent and capecitabine acts as a prodrug of 5-fluorouracil, inhibiting thymidylate synthase. The study is a Phase Ib/II trial sponsored by Henan Cancer Hospital to evaluate the safety and efficacy of this multi-targeted approach.
- Brand names
- XelodaEloxatin
- Other names
- fruquintinib + trastuzumab + oxaliplatin + capecitabinefruquintinib + trastuzumab + CapeOx
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on fruquintinib + trastuzumab + XELOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + trastuzumab + XELOX.